An open source and reduce expenditure ROS generation strategy for chemodynamic/photodynamic synergistic therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32269223.
- Also identified by DOI 10.1038/s41467-020-15591-4 and PMC identifier 7142144.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The therapeutic effect of reactive oxygen species (ROS)-involved cancer therapies is significantly limited by shortage of oxy-substrates, such as hypoxia in photodynamic therapy (PDT) and insufficient hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in chemodynamic therapy (CDT). Here, we report a H<sub>2</sub>O<sub>2</sub>/O<sub>2</sub> self-supplying nanoagent, (MSNs@CaO<sub>2</sub>-ICG)@LA, which consists of manganese silicate (MSN)-supported calcium peroxide (CaO<sub>2</sub>) and indocyanine green (ICG) with further surface modification of phase-change material lauric acid (LA). Under laser irradiation, ICG simultaneously generates singlet oxygen and emits heat to melt the LA. The exposed CaO<sub>2</sub> reacts with water to produce O<sub>2</sub> and H<sub>2</sub>O<sub>2</sub> for hypoxia-relieved ICG-mediated PDT and H<sub>2</sub>O<sub>2</sub>-supplying MSN-based CDT, acting as an open source strategy for ROS production. Additionally, the MSNs-induced glutathione depletion protects ROS from scavenging, termed reduce expenditure. This open source and reduce expenditure strategy is effective in inhibiting tumor growth both in vitro and in vivo, and significantly improves ROS generation efficiency from multi-level for ROS-involved cancer therapies.
Medical subject headings
- Drug Therapy
- Photochemotherapy
- Reactive Oxygen Species